Citations (30)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Jie Zhao, Liangfeng Jiang, Haodong Yang, Lan Deng, Xiaoqing Meng, Jian Ding, Sixing Yang, Le Zhao, Wei Xu, Xiaolong Wang, Zhenping Zhu & Haomin Huang. (2022) A strategy for the efficient construction of anti-PD1-based bispecific antibodies with desired IgG-like properties. mAbs 14:1.
Read now
Read now
Marlena Surowka, Wolfgang Schaefer & Christian Klein. (2021) Ten years in the making: application of CrossMab technology for the development of therapeutic bispecific antibodies and antibody fusion proteins. mAbs 13:1.
Read now
Read now
Articles from other publishers (28)
Sandeep, Suraj H. Shinde, Sakeel Ahmed, Shyam Sunder Sharma & Abhay H. Pande. (2023) Engineered polyspecific antibodies: A new frontier in the field of immunotherapeutics. Immunology.
Crossref
Crossref
Xiaohan Guo, Yi Wu, Ying Xue, Na Xie & Guobo Shen. (2023) Revolutionizing cancer immunotherapy: unleashing the potential of bispecific antibodies for targeted treatment. Frontiers in Immunology 14.
Crossref
Crossref
Gaoya Yuan, Meng Qu, Qi Geng, Wanyuan Dong, Xudong Zhang & Yifeng Li. (2023) Antibody aggregation can lead to reduced Protein A binding capacity and low step yield. Protein Expression and Purification 210, pages 106315.
Crossref
Crossref
Risa Yamada, Ishin Nakahara, Izumi Kumagai, Ryutaro Asano, Takeshi Nakanishi & Koki Makabe. (2023) Construction of IgG–Fab2 bispecific antibody via intein-mediated protein trans-splicing reaction. Scientific Reports 13:1.
Crossref
Crossref
Aleksei K. Misorin, Darya O. Chernyshova & Mikhail S. Karbyshev. (2023) State-of-the-Art Approaches to Heterologous Expression of Bispecific Antibodies Targeting Solid Tumors. Biochemistry (Moscow) 88:9, pages 1215-1231.
Crossref
Crossref
Sameek Singh, Wenzhi Tian, Zachary C. Severance, Santosh K. Chaudhary, Viktoriya Anokhina, Basudeb Mondal, Rajaiah Pergu, Prashant Singh, Uttam Dhawa, Santanu Singha & Amit Choudhary. (2023) Proximity-inducing modalities: the past, present, and future. Chemical Society Reviews 52:16, pages 5485-5515.
Crossref
Crossref
Yan He, Haili Ma, Cong Wang, Zhilong Ai, Qiao Wu, Hongyan Chen & Daru Lu. (2023) A novel brick for bispecific antibody construction. Proteins: Structure, Function, and Bioinformatics 91:8, pages 1065-1076.
Crossref
Crossref
Shiyong Gong & Chengbin Wu. (2023) Efficient production of bispecific antibodies—optimization of transfection strategy leads to high-level stable cell line generation of a Fabs-in-tandem immunoglobin. Antibody Therapeutics 6:3, pages 170-179.
Crossref
Crossref
Adilet Beishenaliev, Yean Leng Loke, Sook Jing Goh, Hui Nee Geo, Malar Mugila, Misni Misran, Lip Yong Chung, Lik Voon Kiew, Steve Roffler & Yin Yin Teo. (2023) Bispecific antibodies for targeted delivery of anti-cancer therapeutic agents: A review. Journal of Controlled Release 359, pages 268-286.
Crossref
Crossref
Mingzhu Liang, Lizhu Wang, Yitai Xiao, Meilin Yang, Chaoming Mei, Yaqin Zhang, Hong Shan & Dan Li. (2023) Preclinical evaluation of a novel EGFR&c-Met bispecific near infrared probe for visualization of esophageal cancer and metastatic lymph nodes. European Journal of Nuclear Medicine and Molecular Imaging 50:9, pages 2787-2801.
Crossref
Crossref
Emilia Rabia, Véronique Garambois, Christine Dhommée, Christel Larbouret, Laurie Lajoie, Yoan Buscail, Gabriel Jimenez-Dominguez, Sylvie Choblet-Thery, Emmanuelle Liaudet-Coopman, Martine Cerutti, Marta Jarlier, Patrice Ravel, Laurent Gros, Nelly Pirot, Gilles Thibault, Eugene A. Zhukovsky, Pierre-Emmanuel Gérard, André Pèlegrin, Jacques Colinge & Thierry Chardès. (2023) Design and selection of optimal ErbB-targeting bispecific antibodies in pancreatic cancer. Frontiers in Immunology 14.
Crossref
Crossref
Julia Harwardt, Stefania C. Carrara, Jan P. Bogen, Katrin Schoenfeld, Julius Grzeschik, Björn Hock & Harald Kolmar. (2023) Generation of a symmetrical trispecific NK cell engager based on a two-in-one antibody. Frontiers in Immunology 14.
Crossref
Crossref
Etsuji Kaneko. (2023) Development in Antibody-based Drug Delivery System Technology抗体を活用したドラッグデリバリー技術の開発状況. Drug Delivery System 38:1, pages 49-57.
Crossref
Crossref
Shrestha Dutta, Swatilekha Ghosh, Abhishek Mishra & Rajgourab Ghosh. (2022) Oncoproteomics: insight into current proteomic technologies in cancer biomarker discovery and treatment. Journal of Proteins and Proteomics.
Crossref
Crossref
Ha Gyeong Shin, Ha Rim Yang, Aerin Yoon & Sukmook Lee. (2022) Bispecific Antibody-Based Immune-Cell Engagers and Their Emerging Therapeutic Targets in Cancer Immunotherapy. International Journal of Molecular Sciences 23:10, pages 5686.
Crossref
Crossref
Sun Min Lim, Kyoung-Ho Pyo, Ross A Soo & Byoung Chul Cho. (2021) The promise of bispecific antibodies: Clinical applications and challenges. Cancer Treatment Reviews 99, pages 102240.
Crossref
Crossref
Mariam Elshiaty, Hannah Schindler & Petros Christopoulos. (2021) Principles and Current Clinical Landscape of Multispecific Antibodies against Cancer. International Journal of Molecular Sciences 22:11, pages 5632.
Crossref
Crossref
Jan P. Bogen, Stefania C. Carrara, David Fiebig, Julius Grzeschik, Björn Hock & Harald Kolmar. (2021) Design of a Trispecific Checkpoint Inhibitor and Natural Killer Cell Engager Based on a 2 + 1 Common Light Chain Antibody Architecture. Frontiers in Immunology 12.
Crossref
Crossref
Jiabing Ma, Yicheng Mo, Menglin Tang, Junjie Shen, Yanan Qi, Wenxu Zhao, Yi Huang, Yanmin Xu & Cheng Qian. (2021) Bispecific Antibodies: From Research to Clinical Application. Frontiers in Immunology 12.
Crossref
Crossref
Jing Shi, Xuesong Chen, Jianbo Diao, Liying Jiang, Lan Li, Stephen Li, Wenzhong Liang, Xiaoying Jin, Yonghui Wang, Colton Wong, Xiaolong Tom Zhang & Francis L.S. Tse. (2021) Bioanalysis in the Age of New Drug Modalities. The AAPS Journal 23:3.
Crossref
Crossref
Xiaotian Zhong & Aaron M. D’Antona. (2021) Recent Advances in the Molecular Design and Applications of Multispecific Biotherapeutics. Antibodies 10:2, pages 13.
Crossref
Crossref
Melvyn LittleMelvyn Little. 2021. Antibodies for Treating Cancer. Antibodies for Treating Cancer
109
125
.
Shuyu Huang, Sander M. J. van Duijnhoven, Alice J. A. M. Sijts & Andrea van Elsas. (2020) Bispecific antibodies targeting dual tumor-associated antigens in cancer therapy. Journal of Cancer Research and Clinical Oncology 146:12, pages 3111-3122.
Crossref
Crossref
Manali S. Sawant, Craig N. Streu, Lina Wu & Peter M. Tessier. (2020) Toward Drug-Like Multispecific Antibodies by Design. International Journal of Molecular Sciences 21:20, pages 7496.
Crossref
Crossref
Strohl & Naso. (2019) Bispecific T-Cell Redirection versus Chimeric Antigen Receptor (CAR)-T Cells as Approaches to Kill Cancer Cells. Antibodies 8:3, pages 41.
Crossref
Crossref
Christian Klein, Wolfgang Schaefer, Joerg T. Regula, Charles Dumontet, Ulrich Brinkmann, Marina Bacac & Pablo Umaña. (2019) Engineering therapeutic bispecific antibodies using CrossMab technology. Methods 154, pages 21-31.
Crossref
Crossref
Shiyong Gong & Chengbin Wu. (2019) Generation of Fabs-in-tandem immunoglobulin molecules for dual-specific targeting. Methods 154, pages 87-92.
Crossref
Crossref
Petra Verdino, Shane Atwell & Stephen J Demarest. (2018) Emerging trends in bispecific antibody and scaffold protein therapeutics. Current Opinion in Chemical Engineering 19, pages 107-123.
Crossref
Crossref